uniQure (NASDAQ:QURE) Price Target Cut to $6.00 by Analysts at Mizuho

uniQure (NASDAQ:QURE) had its price objective decreased by Mizuho from $7.00 to $6.00 in a research note released on Wednesday, Benzinga reports. Mizuho currently has a neutral rating on the biotechnology company’s stock.

QURE has been the topic of a number of other reports. The Goldman Sachs Group lowered shares of uniQure from a buy rating to a neutral rating and reduced their price target for the company from $63.00 to $8.00 in a research report on Thursday, February 29th. StockNews.com upgraded shares of uniQure to a sell rating in a research report on Friday, March 1st. Royal Bank of Canada reiterated an outperform rating and set a $28.00 target price on shares of uniQure in a research report on Tuesday, January 16th. Finally, HC Wainwright reduced their target price on shares of uniQure from $30.00 to $25.00 and set a buy rating on the stock in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $31.91.

uniQure Stock Performance

NASDAQ:QURE traded up $0.01 during midday trading on Wednesday, reaching $4.90. The stock had a trading volume of 71,687 shares, compared to its average volume of 914,806. uniQure has a 1-year low of $4.25 and a 1-year high of $22.48. The firm’s fifty day simple moving average is $5.00 and its 200-day simple moving average is $5.88. The company has a debt-to-equity ratio of 0.49, a current ratio of 8.85 and a quick ratio of 8.68. The stock has a market capitalization of $234.41 million, a P/E ratio of -0.75 and a beta of 0.98.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.01. The company had revenue of $6.69 million for the quarter, compared to the consensus estimate of $3.20 million. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. On average, equities research analysts forecast that uniQure will post -4.49 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In other news, COO Pierre Caloz sold 9,455 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at $554,110.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other uniQure news, CEO Matthew C. Kapusta sold 27,904 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the sale, the chief executive officer now owns 440,839 shares in the company, valued at $2,799,327.65. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Pierre Caloz sold 9,455 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,265 shares of company stock valued at $339,845. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new stake in shares of uniQure during the 3rd quarter worth about $31,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of uniQure by 222.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock worth $42,000 after buying an additional 4,315 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in shares of uniQure during the 3rd quarter worth about $67,000. Laurion Capital Management LP bought a new position in uniQure during the third quarter worth about $73,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in uniQure during the fourth quarter worth about $86,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.